HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Sponsor
Amsterdam UMC, location VUmc
Study ID
NCT02239952
Status
Unknown

Conditions

  • Cancer
  • High-grade Glioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sunitinib — DRUG
    50 mg once daily, oral use for 14 days
  • vandetanib — DRUG
    300 mg, once daily, oral use for 14 days
  • Erlotinib — DRUG
    150 mg, once daily, oral use for 14 days

Study Details

The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue (in the brain) of patients with high-grade gliomas (HGG).

Key Dates

First listed
Sep 15, 2014
Start date
Nov 30, 2014
Status verified
Oct 2020
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021

Study Design

Enrollment
15 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: sunitinib
  • Experimental: vandetanib
  • Experimental: Erlotinib

Primary Outcome Measure

PKI and active metabolites concentrations in tumor tissue [ Time Frame: 2 weeks ]

Central Contacts

Related Studies